Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma Journal Article
| Authors: | Shadman, M.; Salkar, M.; Srivastava, B.; Karve, S.; Emond, B.; Gogna, P.; Manceur, A. M.; Lafeuille, M. H.; Rava, A.; Sun, H.; Howarth, A.; Tomicki, S.; Agatep, B.; Jones, B.; Franceschini, E.; Saifan, C.; Bacchus, S.; Roeker, L.; Stephens, D. M. |
| Article Title: | Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Abstract: | This study used real-world data from three separate United States (US) databases to evaluate dosing patterns and time to next treatment (TTNT) following the first-incident adverse event (AE) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with first-line ibrutinib with and without dose reduction (DR). Median TTNT or death in patients with and without a DR following an AE in each database was as follows: Optum Clinformatics Data Mart (CDM): 59.5 and 30.6 months; ConcertAI: 27.1 and 18.0 months; and Medicare Fee-for-Service (FFS): 49.8 and 22.0 months, respectively. Median TTNT or death in patients with cardiac AEs, with and without a DR, was: Optum CDM: 44.4 and 22.9 months; ConcertAI: 29.9 and 18.3 months; and Medicare FFS: 49.6 and 14.0 months, respectively. Ibrutinib DR was associated with fewer outpatient visits and lower CLL/SLL-related medical costs. These findings suggest that utilizing ibrutinib DR may effectively manage tolerability without compromising clinical efficacy. © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | treatment outcome; aged; aged, 80 and over; middle aged; major clinical study; mortality; diarrhea; drug dose reduction; drug efficacy; hypertension; united states; anemia; protein kinase inhibitor; leukopenia; thrombocytopenia; pyrimidines; retrospective study; febrile neutropenia; lymphocytopenia; rash; protein kinase inhibitors; health care cost; health care utilization; medicare; proportional hazards model; death; pyrazole derivative; heart failure; pyrazoles; hospital patient; outcomes research; outpatient; multivariate analysis; pancytopenia; piperidines; kaplan meier method; epidemiology; drug therapy; pyrimidine derivative; risk reduction; chronic lymphatic leukemia; atrial fibrillation; congestive heart failure; heart ventricle tachycardia; respiratory tract infection; leukemia, lymphocytic, chronic, b-cell; ischemic heart disease; cardiomyopathy; adenine; chronic lymphocytic leukemia; piperidine derivative; musculoskeletal pain; procedures; first-line treatment; small lymphocytic lymphoma; dose reduction; ibrutinib; very elderly; humans; human; male; female; article; b cell chronic lymphocytic leukemia; real-world evidence; drug tapering; emergency department visit |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 66 |
| Issue: | 1 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2025-01-01 |
| Start Page: | 44 |
| End Page: | 53 |
| Language: | English |
| DOI: | 10.1080/10428194.2024.2402814 |
| PUBMED: | 39352001 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
